Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen.

ABSTRACT: Tamoxifen is a prodrug that is primarily metabolized into the pharmacologically active metabolite endoxifen and eventually into inactive metabolites. The herb curcumin may increase endoxifen exposure by affecting phase II metabolism. We compared endoxifen and tamoxifen exposure in breast cancer patients with or without curcumin, and with addition of the bio-enhancer piperine. Tamoxifen (20⁻30mg per day (q.d.)) was either given alone, or combined with curcumin (1200 mg three times daily (t.i.d.)) +/- piperine (10 mg t.i.d.). The primary endpoint of this study was the difference in geometric means for the area under the curve (AUC) of endoxifen. Genotyping was performed to determine CYP2D6 and CYP3A4 phenotypes. The endoxifen AUC_0⁻24h decreased with 7.7% (95%CI: -15.4 to 0.7%;

SUBMITTER: Hussaarts KGAM 

PROVIDER: S-EPMC6468355 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature